Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloitte's 2008 Technolog...(matomalignancies or cancers of the blood...)

Date:11/12/2008

matomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Genoptix served more than 950 ordering physicians nationwide as of the end of the third quarter of 2008. Genoptix reported revenues of $59.3 million, $24.0 million, $5.2 million, $0.7 million and $0.2 million in 2007, 2006, 2005, 2004 and 2003, respectively. The Company recently expanded its laboratory space, and when coupled with a growing sales force and group of hematopathologists, is expected to nearly double its capacity to manage increasing case volumes and support continuing growth.

In addition to ranking on Deloitte's Technology Fast 500, in October Genoptix was named the fastest-growing company in Deloitte's Technology Fast 50 Program for San Diego, a ranking of the 50 fastest-growing technology, media, telecommunications and life sciences companies in the area.

Qualifying Criteria

The Fast 500 ranks the fastest growing technology, media, telecommunications and life sciences companies in North America. It is compiled from Deloitte's regional North American Fast 50 programs, nominations submitted directly to the Fast 500 and public company database research.

Companies are selected based on percentage revenue growth from 2003 to 2007. For the complete Deloitte Technology Fast 500 rankings, please visit http://www.fast500.com.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the bl
'/>"/>

SOURCE Genoptix, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Genoptix Announces Participation at the BIOCOM Investor Conference 2008
2. Genoptix Announces Participation at the UBS Global Life Sciences Conference
3. Genoptix Reports Strong Financial Results For Third Quarter 2007
4. Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China
5. Abt Associates Ranked One of Top 20 U.S. Market Research Firms
6. Aldrichimica Acta Ranked First in Organic Chemistry by Impact Factor
7. Alma Lasers Ranked 9th in Deloitte Technology Fast 50 Award
8. Align Technology, Inc. Ranked 23rd in Deloittes Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies
9. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
10. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
11. WaferGen to Present at the Ninth Annual Beyond Genome Conference